Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-negative Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06472583
What this trial is testing

Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Maria Sklodowska-Curie National Research Institute of Oncology 78
Not applicableNot Yet RecruitingNCT07521202
What this trial is testing

IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE

Who this might be right for
HR+/HER2- Early Breast Cancer
Institut fuer Frauengesundheit 257
Testing effectiveness (Phase 2)Study completedNCT01484080
What this trial is testing

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

Who this might be right for
Breast Cancer
Centro Nacional de Investigaciones Oncologicas CARLOS III 140
Large-scale testing (Phase 3)Active Not RecruitingNCT04964934
What this trial is testing

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 315
Not applicableLooking for participantsNCT07484087
What this trial is testing

Ablation Compare With Surgery for Early Breast Cancer

Who this might be right for
Breast CancerEarly StageHormone Receptor Positive+1 more
Peking University People's Hospital 264
Testing effectiveness (Phase 2)Study completedNCT05150652
What this trial is testing

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerNode-negative Breast Cancer+1 more
Irada Ibrahim-zada 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT05069038
What this trial is testing

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

Who this might be right for
Breast Cancer
University of Nebraska 51
Not applicableActive Not RecruitingNCT06782698
What this trial is testing

Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients

Who this might be right for
Triple Negative Breast Cancer (TNBC)HER2-Positive Breast CancerEarly Breast Cancer+2 more
Centro Hospitalar Universitário de Santo António 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT06394661
What this trial is testing

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 109
Large-scale testing (Phase 3)Study completedNCT01049425
What this trial is testing

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

Who this might be right for
Primary Breast CancerHer2 Non-overexpressing
Women's Cancer Study Group GmbH 3,198
Large-scale testing (Phase 3)Looking for participantsNCT06492616
What this trial is testing

Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Who this might be right for
Breast Cancer
Stemline Therapeutics, Inc. 4,220
Testing effectiveness (Phase 2)UnknownNCT02095743
What this trial is testing

Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer

Who this might be right for
Early Stage Breast Carcinoma
Centre Henri Becquerel 256
Very early researchEnded earlyNCT04102618
What this trial is testing

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

Who this might be right for
Breast Cancer
Oncolytics Biotech 26
Large-scale testing (Phase 3)WithdrawnNCT06884254
What this trial is testing

Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.

Who this might be right for
Early Breast Cancer
EirGenix, Inc.
Large-scale testing (Phase 3)Not Yet RecruitingNCT07827573
What this trial is testing

Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

Who this might be right for
Early Breast CancerEstrogen Receptor-Positive Breast CancerHER2-Negative Breast Cancer
Hoffmann-La Roche 1,500
Large-scale testing (Phase 3)Active Not RecruitingNCT02513394
What this trial is testing

PALbociclib CoLlaborative Adjuvant Study

Who this might be right for
Breast Cancer
Alliance Foundation Trials, LLC. 5,796
Not applicableLooking for participantsNCT07218432
What this trial is testing

The TheraBionic P1 Device in Breast Cancer

Who this might be right for
Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIIA+2 more
Barbara Ann Karmanos Cancer Institute 24
Large-scale testing (Phase 3)UnknownNCT05985187
What this trial is testing

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Who this might be right for
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 412
Early research (Phase 1)Looking for participantsNCT06139107
What this trial is testing

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Who this might be right for
Breast Cancer
Mridula George, MD 15
Large-scale testing (Phase 3)WithdrawnNCT03658213
What this trial is testing

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

Who this might be right for
Breast Cancer
AstraZeneca
Next Page